-
A new round of NRA assessments is complete, and China is playing a more active role in the global vaccine supply
Time of Update: 2022-09-07
The head of the NRA office said: "We will take this assessment as a new starting point, continue to communicate and cooperate closely with the WHO, work together with all relevant departments, continuously improve the ability and level of drug supervision, continue to provide safe and effective, controllable and affordable vaccine drugs for Chinese and the global public, and make greater contributions to the protection and promotion of human health.
-
Guangxi identified 218 medicines as the first batch of Guangxi ethnic medicines
Time of Update: 2022-09-07
, Ltd. includes Guilong ointment, Guilong medicinal wine, tincture of bruises and sprains, compound Shuanghuateng antipruritic liniment, Tiezhuoqingzhuo Pills, Chuanjin Yigan Tablets, Sanshen Yiqi Oral Liquid, Twelve products, including Longan Qiongyu Granules, Antai Yimu Pills, Kanggongyan Granules, Relieving Cough and Asthma Ointment, and Compound Houttuynia Granules, were recognized as Guangxi ethnic medicines .
-
In August, the organization surveyed 766 companies, and the pharmaceutical industry was focused on
Time of Update: 2022-09-07
In the past August, because of the intensive disclosure of the interim report, enterprises have also been significantly investigated by institutions. According to the data, the institution surveyed 7
-
Announcement on the establishment of Shijiazhuang Air Port as a port of import for pharmaceuticals
Time of Update: 2022-09-07
According to the Drug Administration Law of the People's Republic of China, with the approval of the State Council, it was agreed to add Shijiazhuang Air Port as a drug import port. The relevant matt
-
Shanhe Pharmaceutical Co., Ltd. "A preparation method of low-pine density cross-linked carboxymethyl cellulose sodium" won the national invention patent authorization
Time of Update: 2022-09-07
Shanhe Pharmaceutical Auxiliary implements the development strategy of rejuvenating enterprises with science and technology, and adheres to scientific and technological innovation and independent research and development for a long time.
-
In 2022, the performance of H1 head pharmaceutical machine companies is bright, and the agency expects that the annual net profit will continue to grow
Time of Update: 2022-09-07
The agency expects that the annual net profit of the head will continue to grow Since the second half of the year, institutions have made predictions on the 2022 annual performance of listed pharmaceutical machine companies.
-
25 pharmaceutical and biological companies were surveyed by more than 20 institutions!
Time of Update: 2022-09-07
Among them, the net profit attributable to the parent company of two companies in the first half of the year increased by more than 50% year-on-year, namely Adopt Shares and Xiangsheng Medical.
-
Interpretation of the paediatric drug market pattern, track overtaking focuses on subdivisions
Time of Update: 2022-09-07
The underlying logic of the opportunities in the pediatric drug market lies in the huge Chinese market, the increasingly wealthy citizens' attention to children's health, the government's continuous attention and investment in this field, and the advantages of the national system .
-
After the epidemic, the leader may quickly change hands, will Merck have a chance to compete?
Time of Update: 2022-09-07
The new crown epidemic is a thing of the past, and sales are rising and falling As Lei Jun once said: "Standing on the wind outlet, pigs can fly", not to mention the multinational pharmaceutical companies that are already strong in strength, standing on the right outlet, the advantage is naturally facing wireless expansion.
-
In the first half of 2022, the total disclosed transaction volume of China's medical and health service industry is 25.4 billion yuan
Time of Update: 2022-09-07
The report "Trends of M&A Transactions in the Healthcare Industry in the First Half of 2022" released by PricewaterhouseCoopers on the 4th at the 2022 Service Trade Fair pointed out that the repeated epidemics in many places in the first half of the year affected the development of investment and financing M&A activities to a certain extent, and the capital market was active.
-
62 varieties have been evaluated, and 12 varieties have been evaluated for the first time! Hainan General Sanyo, Yangtze River, Huahai...
Time of Update: 2022-09-07
Figure 6 Top 2022 in august 8 for the number of enterprise declaration acceptance numbers Data source: Yaozhi data, Yaozhi consulting collation Hainan General Sanyo Pharmaceutical Co.
-
The production of medicinal herbs has been reduced to a sharp increase in prices! Chinese medicine raw materials are facing many tests
Time of Update: 2022-09-07
Ups and downs It has the greatest impact on rhizomes, fruit seeds and animals From the perspective of rising and falling varieties, the provinces with a high proportion of rising varieties of raw materials are mainly concentrated at the end of the irrigation areas of the Yangtze River Basin.
-
Focus on the medical reform in Huzhou, Zhejiang: realize that the grass-roots people have "medical" reliability
Time of Update: 2022-09-07
Municipal public hospitals achieve full coverage of "top three", and 80% of municipal hospitals have reached the level of A and above in the national examination; "Healthy City Model City" is the third in the country and the first in Zhejiang; Medical reform was selected into the list of best practices for the first batch of high-quality development and construction of common prosperity demonstration zones in Zhejiang Province, and was the first in Zhejiang's assessment for 4 consecutive years.
-
10% opposition to oral price governance? Who is blocking the price reduction of dental implants?
Time of Update: 2022-09-07
On September 2, the National Medical Insurance Bureau issued the notice on the public solicitation of comments on the previous "Notice on Carrying out Special Governance of Oral Implant Medical Servi
-
Policy interpretation of the Measures for the Supervision and Administration of Drug Network Sales
Time of Update: 2022-09-07
I. What is the background of the formulation of the Measures for the Supervision and Administration of Drug Network Sales (hereinafter referred to as the Measures)? In recent years, with the rapid de
-
The imported nine-valent HPV vaccine is suitable for the expansion of the domestic population. Can the four-valent HPV vaccine be used again?
Time of Update: 2022-09-07
(Finish)Severe allergic reactions to any of the active ingredients or excipients On the 30th, the "Merck China" WeChat account announced that the new indication of its nine-valent human papillomavirus vaccine (nine-valent HPV vaccine) has been approved by the National Medical Products Administration of China.
-
The collection of proprietary Chinese medicines covers most of the provinces, and the pressure of price reduction is unprecedented!
Time of Update: 2022-09-07
On the other hand, the winning products in the collection also face competition from proprietary Chinese medicines that have not entered the collection of the same indications, the latter has not reduced prices, and there is more profit space for market promotion and competition for the former market.
-
Affected by rising costs, a large number of pharmaceutical companies will go bankrupt and go bankrupt!
Time of Update: 2022-09-07
In fact, looking at the entire pharmaceutical industry, not only overseas pharmaceutical companies, but also domestic pharmaceutical companies are generally under pressure due to factors such as rising costs, centralized procurement, medical insurance cost control, and fierce market competition, and gradually go bankrupt, closed down .
-
It is expected to reach a market of 28.8 billion yuan! Domestic pharmaceutical companies actively lay out the CAR-T therapy track
Time of Update: 2022-09-07
In addition to the expansion of more indications, Fosun Kate's second CAR-T cell therapy product, FKC889, for the treatment of adult patients with relapsed/refractory sleeve cell lymphoma (r/r MCL) after second-line or above treatment, was approved for clinical trials in China in March 2022.
-
Since September, a large number of domestic medical consumables have begun to reduce prices
Time of Update: 2022-09-06
With the implementation of the selected results, Hebei Province includes ultrasonic scalpels, disposable nasobiliary drainage tubes, thoracic (abdominal) punctures, disposable Use of central venous catheter, disposable oropharyngeal airway, anesthesia line, analgesia pump, disposable papillotomy (three-lumen), endotracheal tube, bone cement, infusion port, trap, pectus excavatum orthosis , ligatures, chest (abdominal) drainage tubes, disposable pressure sensors, intracoronary shunts, vascular closure systems and other 22 types of medical consumables to achieve price reductions .
